The OCMX™ is pleased to announce the listing of Sequella Incorporated to its online portal which offers Investors and Advisors the ability to participate in this opportunity.

TORONTO, ON, May 24, 2018 /24-7PressRelease/ — Sequella is a private, clinical stage pharmaceutical company that addresses the challenge of antibiotic resistant bacterial diseases by discovery and development of first in class antibiotics with novel mechanisms of action.

The OCMX™ is pleased to announce the listing of Sequella Incorporated to its online portal which offers Investors and Advisors the ability to participate in this opportunity.

The OCMX™ has spent considerable time completing its due diligence on Sequella Incorporated and concluded that there is indeed a tremendous opportunity for Investors and Advisors.

The OCMX™ noted that Sequella Incorporated exhibits the main components of any solid investment opportunity, namely a solid management team, a great track record, and a number of key competitive advantages.


Carol A. Nacy, Chief Executive Officer | Dr. Nacy is an accomplished scientist and businesswoman, with 20 years of basic science research and science management in academic settings (Fellow of the American Academy of Microbiology) and an additional 25 years of starting companies and leading science for product development in three U.S.-based biotechnology companies. She and the management team took her first company public on NASDAQ and her second company was acquired by a large biotechnology company. Her passion is in understanding and devising ways to prevent or treat infectious diseases that are global health threats, especially antibiotic resistant bacteria. She co-founded Sequella in 1997 and has led her team to discover and develop several novel antibiotics now in clinical trials that address diseases that infect billions of people worldwide, kill millions of people annually, and are underserved by pharmaceutical and biotechnology companies.

Mark Rampy, Chief Business Officer | Dr. Rampy has over twenty years of experience in the biotechnology and pharmaceutical sectors, including leadership roles at early stage and venture-backed companies, and mid-large cap public pharmaceutical/biotechnology companies. His areas of expertise include business/corporate strategy, business development, structure, negotiation and closing of complex licensing transactions and strategic alliances, as well as technology and product development. Prior to Sequella, he was CEO of several start-ups (Theraly Pharmaceuticals, and CohBar, Inc), VP Business Development Biologics and Specialty Products, Teva Pharmaceuticals, Founder and Chief Business Officer of CoGenesys, Inc. a company which was acquired by Teva. Prior to CoGenesys, he was with Human Genome Sciences, Inc. for eleven years, in positions of increasing responsibility in R&D and Business Development, the most senior of which was Head of Business Development.

David Mc Neeley, MD, Chief Medical Officer | Dr, Mc Neeley is an MD and specialist in pediatric infectious diseases, public health and tropical medicine. He was on the faculty of Weill Cornell Medical Center in the Division of Pediatric Infectious Diseases, working primarily in HIV and TB clinics, as well as general pediatric infectious disease clinic and in-hospital consultations, including rotations through Memorial Sloan-Kettering Medical Center. He has worked extensively in international health settings, including serving as medical director of an all-service hospital and an extensive community health program serving nearly 250,000 people. He conducted clinical and field research in bacterial infections, tuberculosis, human immunodeficiency virus infection and parasitic diseases such as schistosomiasis and filariasis. For the past 14 years, Dr. Mc Neeley has worked in anti-infective drug development (antibiotics, antivirals, and anti-parasitic drugs) in large pharmaceutical companies (Johnson & Johnson, Novartis) and brought the first new TB drug, bedaquiline, through the clinic and to worldwide registration for J&J.

Leo Einck, VP Industry Affairs | Dr. Einck has been building companies for the last 33 years: he was the 1st employee of Hemispherix and built out manufacturing facilities and executed clinical trials; he was the 8th employee of EntreMed and managed the relationship with a Harvard research group whose technology enabled the company to have an initial public offering; and he founded Sequella and Sequella Global TB Foundation with Dr. Nacy and has participated in all aspects of growing the company. His current role includes managing the GMP manufacturing and testing of Sequella’s antibiotics and research on TB diagnostics.


The OCMX™ is literally changing how companies and investment funds generate exposure in the marketplace and raise funds as we know it. The OCMX™ serves both public and private companies along with investment and mutual funds which need to raise additional funds or gain significant market exposure. It does this by way of connecting the relevant companies, funds, investors, and advisors all in one online transparent portal. The OCMX™ (P2P Financial Inc.) launched in September of 2009 out of Toronto but has since expanded its operations to include Quebec, Alberta, Manitoba, and British Columbia.

The OCMX™ connects investors and advisors directly with companies and investment funds seeking to raise funds or gain broad market exposure. The OCMX™ provides an open venue for innovative growth companies and leading investment funds to generate market awareness, raise funds, or connect with investors and advisors. The OCMX™ provides companies, funds, investors, and advisors instant access to its Online Portal so that they can actively source and connect with their next opportunity, advisor, investor, client, or financing partner.

Contact Us
TD Canada Trust Tower
161 Bay Street, 45th Floor
Toronto, Ontario, M5J 2S1
Tel: 1-866-209-6862
Email: [email protected]

For the original version of this press release, please visit here